3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
32
Colonic Neoplasms
20
Rectal Neoplasms
11
Carcinoma, Hepatocellular
7
Neoplasm Metastasis
5
Stomach Neoplasms
2
Neoplastic Cells, Circulating
2
Neoplasms
2
Liver Neoplasms
2
Recurrence
1
Peritoneal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Oligometastatic Gastric Adenocarcinoma
1
Neuroendocrine Tumors
1
Neoplasms, Second Primary
1
Neoplasm, Residual
1
Neoplasm Recurrence, Local
1
Margins of Excision
1
Locally Advanced Rectal Cancer
1
Gastro-enteropancreatic neuroendocrine tumor
1
Gallbladder Neoplasms
1
Cholangiocarcinoma
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
13
Cisplatin
10
Capecitabine
7
pembrolizumab
3
Oxaliplatin
3
Leucovorin
3
Chemotherapy, Adjuvant
3
durvalumab
2
Watchful Waiting
2
Fluorouracil
2
Dihematoporphyrin Ether
2
zanidatamab
1
becatecarin
1
Tegafur
1
Taxes
1
Somatostatin
1
S 1 (combination)
1
Platinum
1
Phototherapy
1
Photochemotherapy
1
Ondansetron
1
Neoadjuvant Therapy
1
Laser Therapy
1
Irinotecan
1
Folfox protocol
1
Fentanyl
1
Escitalopram
1
Epirubicin
1
Dexamethasone
1
Chemoradiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Gallbladder Neoplasms
×
Folfox protocol
×
Clear all
NCT07265674
2026-05-14
Beacon-BTC
J-Pharma Co., Ltd.
Phase 3
Recruiting
480 enrolled